DR-273 Tackling primary and acquired resistance to PD-(L)1 checkpoint inhibition in advanced non-small cell lung cancer

In recent years the treatment of patients with lung cancer has improved tremendously with the introduction of immunotherapy. This therapy helps the patient’s own immune system to attack the tumor cells. Unfortunately, not all patients benefit from this treatment. We want to better understand the mechanisms used by the tumor cells to escape the effect of immunotherapy. By improving our knowledge of these mechanisms, we hope to contribute to new cancer therapies in the future.

Willemijn Theelen, Netherlands Cancer Institute, The Netherlands